BioAsset

Healthcare finance intelligence for the next generation of analysts, investors, and scientists.

Latest Insights

Research & Analysis

Deep dives, company analyses, educational primers, and open financial models from our global analyst team.

Company Analysis

$6.7B: Merck's Leukemia Drug Acquisition That Could Shake Up The Market

Alay Galvankar · 5 slides
Industry Trends

Inside the Failure of Semaglutide in Alzheimer's: GLP-1 Reality Check

Henry Bourtman · 4 slides
Deep Dive

UK Biobank: Turning Biological Data into Drug Discovery

Brendan Seo · 5 slides
Industry Trends

Saliva, Stress, and Startups: The Rise of Cortisol Testing

Joy Wu · 5 slides
Memo + Model

Tectonic Therapeutic (TECX): Long Thesis Memo & Financial Model

Benjamin Shar · 12 pages · PDF + XLSX
Memo (PDF)Model (XLSX)
Our Analysts

Our Team

BioAsset is built on a simple belief: the best work happens when curious people are given real ownership. Our analysts aren’t siloed into rigid roles or buried under busywork. Every member of the team contributes meaningfully to research, writing, and editorial review, and no one’s contribution matters less than anyone else’s.

We sit at the intersection of life sciences and finance, and our team reflects that. Our analysts come from diverse academic backgrounds spanning biochemistry, economics, public health, and beyond, united by a genuine curiosity about how science creates value. That cross-disciplinary perspective is what makes our content sharper than what you’d find at a typical student org.

We also believe great output starts with genuine interest. Analysts have the flexibility to pursue the topics that excite them, whether that’s an FDA catalyst, a pipeline valuation, or a landmark deal reshaping the industry. When people care about what they’re researching, the quality speaks for itself.

If you want to do serious, professional-level work in healthcare finance alongside people who are just as driven and curious as you are, BioAsset is the place.

Dmitry Vysotskiy
NYU Stern, Finance
Founder & CEO
Henry Bourtman
Santa Fe College, Finance
COO
Alay Galvankar
NYU, Global Public Health & Biology
Lead Analyst
Joy Wu
NYU, Biology & Business Studies
Outreach
Brendan Seo
NYU, Economics
Research Analyst
Jingqiu Tian
Cambridge, Bio Nat Sci
Research Analyst
Daniel Warren
NYU, Biochemistry
Research Analyst
Yaz Arulthasan
NYU, Biology
Outreach
Benjamin Shar
NYU Stern, Finance
Research Analyst
Sharath Venkatesan
NYU, Biochemistry
Research Analyst
Neev Mohindroo
Rutgers, Finance & Bio
Research Analyst

Growing team · Apply to join →

Conversations

Interviews & Media

Conversations with leaders across biotech, healthcare finance, and the life sciences. Watch interview highlights on our Instagram here.

Our Mission

The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians.

We publish rigorous, accessible research. We build open financial models. We train student analysts to think across disciplines. And we do it all in public.

7,000+
Followers
10+
Members
8+
Collaborators
Community

Join the Conversation

Whether you want to read, write, model, or just learn, there's a place for you.

Apply to the TeamCollaborate
© 2026 BioAsset. All rights reserved.
Scroll
Top Insights Team Conversations About
From the team behind BioAsset

TechAsset

Decoding the engineering behind the valuation. TechAsset sits at the intersection of deep tech and finance, translating hardware, software, infrastructure, and engineering complexity into clear market insight.

Research

Our Research

Weekly analysis, expert interviews, deal breakdowns, and startup coverage for people who want to understand the technology and the money behind it.

Quantum Computing

Inside Quantum Computing: Qubits, Chip Designs, and the Future of AI

How quantum hardware works, why the biggest tech companies care, and where chip design may matter most.

Evan Vysotskiy · 5 slides
Semiconductors

Breaking Down the Memory Wall and Discussing the DRAM ETF

A look at high-bandwidth memory, supply constraints, and the investment case around the DRAM theme.

Aiden Shkolnik · 4 slides
AI

AI Constitutions: The Rise of Philosophers in AI

Why moral reasoning, safety rules, and philosophical guardrails are becoming part of the AI buildout.

Dmitry Vysotskiy · 6 slides
Coverage Areas

What We Track

Computing

Quantum Computing

Heavily hyped, rarely understood, and increasingly valued on technical nuance rather than headlines.

Hardware

Semiconductors & AI Hardware

GPUs, custom silicon, HBM memory, and the foundry and packaging layer behind AI scale.

Infrastructure

AI Infrastructure

Data centers, power, cooling, networking, and the true cost of compute.

Deep Tech

Energy & Deep Tech

Nuclear, SMRs, grid technology, batteries, and capital-intensive engineering bets.

Automation

Robotics & Automation

Humanoids, industrial systems, and the actuator and sensor supply chain.

Crossover

TechBio & AI Drug Discovery

Where TechAsset meets BioAsset, covered from the engineering and healthcare sides.

Who We Are
We explain the engineering the market is mispricing.
Modern technology is advancing fast and growing more complex by the day.
TechAsset deciphers the hardware, software, and engineering behind companies and innovation, then translates it into financial insight.
We are not a news journal. We produce educated insights and connections with proper reasoning and backing.
We also interview startup CEOs and industry professionals to bring readers perspectives from inside the industry.
Where We're Heading

Building the future of TechAsset.

Startup deep dives

What founders are solving, how the product works, and why it matters.

Founder interviews

Industry experts and operators explaining the technical story in their own words.

BioAsset x TechAsset crossovers

TechBio and AI drug discovery covered from both sides.

Technical pitches

Sharper pitches that hone in on the engineering and the economics.

Starting Team

The analysts behind TechAsset

A focused team built to make complex technical topics digestible for a general audience without flattening the engineering.

Aiden Shkolnik

Aiden Shkolnik

Co-Founder • Pace Lubin '29 • Finance

Drawn to TechAsset for the chance to do real market research while going deeper on the tech sector, analyzing trends, weighing emerging technologies, and making complex topics clear and engaging.

Evan Vysotskiy

Evan Vysotskiy

Co-Founder • Brooklyn Tech '28 • Electrical Engineering & Applied Math

Interested in STEM and the finance side of technology, with a focus on making complex topics more digestible for a general audience.

What We Cover

Coverage built around technical depth.

The first TechAsset tracks are designed around areas where valuation depends on understanding the engineering: compute, chips, infrastructure, energy, robotics, and the TechBio crossover.

Join Us

Join the growing audience learning technology finance.

Help build TechAsset through research, interviews, startup coverage, and technical explainers for readers who want more than surface-level tech commentary.

Past Collaborators
Work With Us

Collaborate with BioAsset

We partner with professionals, students, and organizations operating at the intersection of life sciences and capital markets. If your work touches biotech, healthcare finance, or drug development, there's likely a way we can work together.

Collaboration Tracks

How to Get Involved

Whether you're an industry veteran, an aspiring analyst, or a student organization, we've built structured ways to collaborate.

For Professionals

Expert Interviews

Share your perspective with our audience of 7,000+ followers across biotech, pharma, and healthcare finance.

Format: 30–45 min recorded conversation, published as editorial content across our channels.

Ideal for: Biotech investors, sell-side analysts, pharma executives, academic researchers, and clinician-scientists.

Express Interest
For Students & Early-Career

Guest Analysis

Publish a biopharma or healthcare finance deep-dive with full author credit, reviewed by our editorial team.

Format: Written analysis piece — company breakdown, sector overview, or financial model walkthrough — edited and published under your name.

Ideal for: Students, graduate researchers, and early-career professionals building a public portfolio in healthcare finance.

Featured each month: One standout submission is selected as our Research Post of the Month, distributed across all BioAsset channels for maximum visibility.

Submit a Pitch
For Organizations

Partnerships

We work with student groups, platforms, and organizations on cross-promotion, co-produced content, and joint events.

Format: Flexible — audience swaps, co-hosted panels, shared research projects, or event sponsorship.

Ideal for: University finance and biotech clubs, healthcare-focused media platforms, and life sciences organizations.

Start a Conversation
Get in Touch

Have Something Else in Mind?

Reach out directly and we’ll find the right way to work together.

bioasset@bioasset.info